High dose chemotherapy with autologous stem cell support for breast cancer

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 381-389

  Vahdat, Linda ^a   Antman, Karen ^a  

^a Division of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; DRUG MEGADOSE; GENE THERAPY; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 0030731819     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00004     Document Type: Review

References (97)

1. Parker S, Tong T, Bolden S, Wingo P: Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5-27.
2. Clark G, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987, 5:55-61.
3. Mick R, Begg CB, Antman K, Korzun AH, Frei E III: Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989, 13:33-38.
4. Gianni L, Munzone E, Capri G, et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995, 13:2688-2699.
5. Greenberg P, Hortobagyi G, Smith T, Ziegler L, Frye D, Buzdar A: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14:2197-2205. Reviews natural history of stage 4 breast cancer from a large database.
6. Frei III E, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585-594.
7. Frei III E, Antman K, Teicher B, Eder P, Schnipper L: Bone marrow autotransplantation for solid tumors: prospects. J Clin Oncol 1989, 7:515-526.
8. Hryniuk WM, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281-1287.
9. Antman K, Rowlings P, Vaughn W, et al.: High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997, 15:1870-1879. Excellent report of outcomes of autotransplants for breast cancer from the largest transplant database available.
10. Ross A, Farmer S, Moss T, et al.: Tumor contamination of peripheral blood stem cell collections from breast cancer patients: influence of clinical status at time of pheresis [abstract]. Breast Cancer Res Treat 194, 32(suppl):63.
11. Fields K, Moscinski L, Trudeau W, Perkins J, Pach L, Elfenbein G: High incidence of bone marrow micrometastases using the polymerase chain reaction technique in patients with high risk stage II and stage III breast cancer following adjuvant therapy: clinical correlates [abstract]. Breast Cancer Res Treat 1994, 32(suppl):63.
12. Myers S, Mick R, Williams S: High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994, 13:449-454.
13. Seong D, Mehra R, Andersson B, et al.: Autologous bone marrow infusion does not contribute to relapse following high dose tandem chemotherapy for recurrent or metastatic breast cancer [abstract]. Blood 1994, 84(suppl 1):210a.
14. Shpall E, Franklin W, Jones R, et al.: Transplantation of CD34+ selected progenitor cells into breast cancer patients following high-dose chemotherapy [abstract]. Am Soc Blood Marrow Transplant 1995, 1 (suppl).
15. Vredenburgh J, Silva O, deSombre K, et al.: The significance of bone marrow micrometastases for patients with breast cancer and ≥ 10+ lymph nodes treated with high-dose chemotherapy and hematopoletic support [abstract]. Proc Am Soc Clin Oncol 1995, 14:317.
16. Passos-Coelho J, Ross A, Davis J, et al.: Bone marrow micrometastases in chemotherapy responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994, 54:2366-2371.
17. Myklebust A, Godal A, Juell S, Pharo A, Fodstad O: Comparison of two antibody-based methods for elimination of breast cancer cells from human marrow. Cancer Res 1994, 54:209-214.
18. Bergan R, Hakim F, Schwartz G, et al.: Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996, 88:731-741.
19. Wu A, Rabkin S, Maruzas R, Thein M, Mazumder A: Bone marrow purging by attenuated multi-mutated herpes simplex virus-1 [abstract]. Proc Am Soc Clin Oncol 1997, 16:91a.
20. Garcia-Sanchez F, Pizzorno G, Cooperberg M, Krause D, Crystal R, Deisseroth A: Effective bone marrow purging using an adenovirus vector containing the prodrug activation unit cytosine deaminase [abstract]. Proc Am Soc Clin Oncol 1997, 16:91a.
21. Vahdat L, Antman K: Dose-intensive chemotherapy in breast cancer. In High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, edn 2. Edited by Armitage J, Antman K. Philadelphia: Williams & Wilkins; 1995:802-823.
22. Rowlings P, Antman K, Horowitz M, et al.: Breast Cancer Working Committee of the Autologous Bone Marrow Transplant Registry (ABMTR) [abstract]. Proc Am Soc Clin Oncol 1995, 14:325.
23. Dasgupta A, Rajagopal C, Efird J, et al.: High-dose cyclophosphamide/carboplatin and autologous bone marrow transplantation/peripheral blood stem cell transplantation for metastatic breast cancer: an analysis of prognostic factors [abstract]. Proc Am Soc Hematol 1994, 85.
24. Dunphy F, Spitzer G, Fornoff JF, et al.: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994:2157-2167.
25. Doroshow J, Somlo G, Ahn C, et al.: Prognostic factors predicting progression-free and overall survival in patients with responsive metastatic breast cancer treated with high-dose chemotherapy and bone marrow stem cell reinfusion [abstract]. Proc Am Soc Clin Oncol 1995, 14:319.
26. Ayash L, Antman K, Wheeler C, et al.: High-dose multimodality therapy with autologous stem cell cupport for stage IIIB breast cancer the DFCI/BIH experience [abstract 936]. Proc Am Soc Clin Oncol 1995, 14:318. Innovative approach to inflammatory breast cancer.
27. Bearman S, Jones R, Shpall E, Stemmer S, Purdy M, Myers S: High-dose chemotherapy with autologous progenitor cell support for stage IV NED breast cancer [abstract]. Breast Cancer Res Treat 1994, 32(suppl):65.
28. Stemmer S, Jones R, Bearman S, Purdy M, Myers S, Shpall E: Intensive Taxol/cyclophosphamide/cisplatin with autologous hematopoietic cell support [abstract]. Proc Am Soc Clin Oncol 1994, 13:105.
29. Spitzer G, Champlin R, Seong D, et al.: Repetitive high-dose therapy (HDT) tolerance and outcome in stage IV breast cancer. In Seventh International Symposium On Autologous Bone Marrow Transplantation Edited by Dicke KA, Keating A. Houston, TX: University of Texas Press; 1994.
30. Vukelja S, Baker W, Burrel L, et al.: High-dose taxol, cyclophosphamide, and cisplatin with stem cell support in treatment of metastatic breast cancer. In Autologous Bone Marrow Transplantation: Proceedings of the International Symposium. Edited Dicke KA, Armitage JO, Dicke-Evinger MJ. Houston, TX: University of Texas Press; 1994:74.
31. Rahman Z, Frye D, Champlin R, et al.: Phase I trial of multiple cycle escalating dose doxorubicin, paclitaxel and cyclophosphamide with peripheral blood progenitor cells and G-CSF support in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:92a. Very high complete response rate in this trial.
32. Mayordomo J, Yubero a, Cajal R, et al.: Phase I trial of high-dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue [abstract]. Proc Am Soc Clin Oncol 1997, 16:102a.
33. Bhargava P, Marshall J, Rizvi N, et al.: A study of TNP-470 in patients with advanced cancer [abstract]. Proc Am Assoc Cancer Res 1997, 38:221.
34. Chou J, Moasser M, Kohl N, et al.: The farnesyl transferase inhibitor induces G1 arrest in Ras-transformed human mammary epithelial cells in combination with epidermal growth factor receptor blockade [abstract]. Proc Am Assoc Cancer Res 1997, 38:63.
35. Brown P, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995, 6:967-974.
36. Vahdat L, Balmadeda C, Papadopoulos D, et al.: Tandem high dose chemotherapy with escalating paclitaxel, melphalan, and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in responding metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:99a.
37. Mehra R, Browne V, Rondon G, Mirza N, Champlin R: Phase I/II study of multiple course high dose CTC with PBSC infusion for metastatic beast cancer. Proc Am Soc Clin Oncol 1997, 16:100a.
38. Wallerstein R, Spitzer G, Dunphy F, et al.: A phase II study of mitoxantrone, etoposide, thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 1990, 8:1782-1788.
39. Vahdat L, Crown J, Reich L, et al.: Granulocyte colony-stimulating factor (G-CSF) and peripheral blood progenitors facilitate rapidly cycled courses of high-dose chemotherapy in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1993, 12:99.
40. Crown J, Vahdat L, Raptis G, et al.: Rapidly cycled courses of high-dose chemotherapy supported by filgrastim and peripheral blood progenitors [abstract]. Proc Am Soc Clin Oncol 1994, 13:110.
41. Crown J, Raptis G, Vahdat L, et al.: Rapid administration of sequential high-dose cyclophosphamide, melphalan, thiotepa supported by filgrastim + peripheral blood progenitors in patients with metastatic breast cancer: a novel and very active treatment strategy [abstract]. Proc Am Soc Clin Oncol 1994, 13:110.
42. Shapiro CL, Hurd D, Clark P, et al.: Repetitive cycles of cyclophosphamide, thiotepa and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients [abstract]. Proc Am Soc Clin Oncol 1994, 13:66.
43. Ayash LJ, Elias A, Wheeler C, et al.: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994, 12:37-44.
44. Broun E, Sledge G, Ansari R, et al.: Two cycles of high-dose chemotherapy with autologous bone marrow rescue (ABMR) as initial treatment for stage IV breast cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:85.
45. Livingston R, Collins C, Willimas M, Thompson T, Rivkin S: Determinants of outcome after consolidation for stage IV breast cancer with cyclophosphamide, etoposide and cisplatin (CEP) [abstract]. Proc Am Soc Clin Oncol 1994, 13:58. Feasibility study of tandem transplants in metastatic breast cancer - a new approach.
46. Bitran JD, Samuels B, Hanauer S, Johnson L: Tandem high dose chemotherapy in women with stage IV breast cancer. In Proceedings of the 7th International Symposium on Autologous Bone Marrow Transplantation. Edited by Dicke KA, Armitage JO, Dicke-Evinger MJ. Houston, TX: University of Texas Press; 1994:72.
47. Patrone F, Ballestreto A, Ferrando F, et al.: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor cell rescue for metastatic breast cancer. J Clin Oncol 1995, 13:840-846.
48. Wieden P, Sullivan K, Fluornoy N, et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow autografts. N Engl J Med 1979, 300:1068-1073.
49. Kennedy M, Vogelsang G, Beveridge R, et al.: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993, 11:478-484.
50. Kennedy M, Vogelsang G, Jones R, et al.: Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994, 12:249-257.
51. Soiffer R, Murray C, Cochran K, et al.: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992, 79:517-526.
52. Hess AD: Syngeneic/autologous graft-vs-host disease: mobilization of autoimmune mechanisms as antitumor immunotherapy. Cancer Control 1994:201-207. Innovative approach to induce an autologous graft-versus-host disease in breast cancer patients.
53. Gottlieb D, Brenner M, Heslop H, et al.: A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989, 60:610-615.
54. Tarantolo S, Singh R, Reed E, et al.: Immune augmentation with low-dose continuous infusion interleukin-2 after high-dose therapy and stem cell transplantation for patients with metastatic breast cancer [abstract]. Proc Am Assoc Cancer Res 1997, 38:610a.
55. Recchia F, DeFilippis S, Guernero G, Rea S, Frati L: Immunotherapy with interleukin-2 after high-dose chemotherapy with peripheral blod progenitor cell support for solid tumors: preliminary results of a randomized trial [abstract]. Proc Am Soc Clin Oncol 1997, 16:113a.
56. deMagalhaes-Silverman M, Donnenberg A, Elde E, et al.: Post-transplant immunotherapy in metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:95a.
57. Kennedy M, Davidson N, Fetting J, et al.: Phase I and immunologic study of interleukin-2 to augment cyclosporine A-induced autologous graft-versus-host disease after high dose chemotherapy in women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:106a.
58. Meehan K, Verman U, Frankel S, et al.: Immunotherapy with IL-2 and a-IFN after PBSC transplantation for women with breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:94a.
59. Gilewski T, Adluri R, Zhang S, Houghton A, Norton L, Livingston P: MUC-1 keyhole limpet hemocyanin conjugate plus QS-21 vaccination of high risk breast cancer patients with no evidence of disease [abstract]. Proc Am Soc Clin Oncol 1997, 16:438a.
60. Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994, 29:127-138.
61. Ward M, Richardson C, Pioli P, et al.: Transfer and expression of the human multiple drug resistance gene in human CD34 + cells. Blood 1994, 84:1408-1414.
62. Hesdorffer C, Ayello J, Ward M, et al.: A phase I clinical trial using MDR-tranduced marrow and/or peripheral blood CD34+cells [abstract]. Proc Am Soc Clin Oncol 1997, 16:88a. Represents a new approach to treating advanced breast cancer.
63. Izbecka E, Kim D, Degen D, VonHoff D: Effects of ONYX adenovirus preparations on human tumor colony forming units [abstract]. Proc Am Soc Clin Oncol 1997, 16:433a.
64. Talmadge J, Watanabe T, Kuxzynski C, et al.: Purging properties of p53 adenovirus-mediated gene transfer into breast cancer cells using protocols which are nontoxic for human C34+ cells [abstract]. Proc Am Assoc Cancer Res 1997, 38:6. One of the first published gene therapy trials in advanced cancer, representing a new modality to treat patients.
65. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
66. Baselga J, Tripathy D, Mendelsohn J, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast. J Clin Oncol 1996, 14:737-744.
67. Gianni A, Siena S, Bregni M, et al.: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997, 15:2312-2321.
68. Peters W, Berry D, Vredenburgh J, et al.: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes [abstract]. Proc Am Soc Clin Oncol 1995, 14:317.
69. Tajima T, Tokuda Y, Kubota M, Mitomi T: Adjuvant chemotherapy supported by autologous bone marrow transplantation in breast cancer [abstract]. Proc Am Soc Clin Oncol 1990, 9:31.
70. Tajima T, Sonoda H, Kubnota M, et al.: High-dose combination chemotherapy with autologous bone marrow transplantation in breast carcinoma. Gan To Kagaku Ryoho 1983, 10:840-847.
71. Tajima T, Sonoda K, Tokuda Y, et al.: High-dose chemotherapy supported by autologous bone marrow transplantation in solid tumors. Tokai J Exp Clin Med 1988, 8:41-51.
72. Tajima T, Tokuda Y, Ohta M, et al.: Role of autologous bone marrow transplantation in cancer chemotherapy. Low Temp Med 1989, 15:44-50.
73. Somlo G, Doroshow J, Forman S, et al.: High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994, 73:1678-1685.
74. Saez R, Selby G, Slease R, Epstein R, Confer D: Autologous bone marrow transplantation in breast cancer: analysis of factors related to outcome in 65 consecutive patients [abstract 183]. Proc Am Soc Clin Oncol 1992, 11:89.
75. Holland H, Klein L, Geller R, et al.: High dose chemotherapy with cyclophosphamide, thiotepa and carboplatin and autologous bone marrow transplant for patients with stage II/III breast cancer and 10 or greater lymph nodes: two year follow-up report [abstract]. Proc Am Soc Clin Oncol 1995, 14:112.
76. Bearman S, Overmoyer B, Bolwell B, et al.: High dose chemotherapy with autologous peripheral blood progenitor cells for primary breast cancer in patients with 4-9 involved axillary lymph nodes: a feasibility study [abstract]. Proc Am Soc Clin Oncol 1996, 15:333.
77. Hussain A, Plumer M, Vredenburgh J, et al.: High dose chemotherapy with cyclophosphamide, cisplatin and BCNU and autologous bone marrow and peripheral blood progenitor cells for stage II/III breast cancer involving 4-9 axillary lymph nodes [abstract]. Proc Am Soc Clin Oncol 1996, 15:350.
78. Lluch A, Sola C, Hornedo J, et al.: High-dose chemotherapy and autologous peripheral stem cell transplantation after neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer [abstract]. Proc Am Soc Clin Oncol 1996, 15:353.
79. Mulder N, Graaf V, Sleijfer D, et al.: Induction chemotherapy followed by intensification with high-dose chemotherapy and autologous bone marrow and/or peripheral stem cell reinfusion in locally advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1995, 14:117.
80. Schwartzberg L, Birch R, Hazelton B, et al.: High-dose chemotherapy with peripheral blood stem cell support for high risk stage II and stage III breast cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:97.
81. Fields K, Perkins J, Ballester O, et al.: Time to relapse following high-dose chemotherapy for the treatment of poor prognosis breast cancer: durable remissions beyond 24 months [abstract]. Breast Cancer Res Treat 1994, 34(suppl):63.
82. Fields KK, Sale RA, Zorsky PE, et al.: A phase I-II study of high-dose ifosfamide, carboplatin, and etoposide and autologous bone marrow rescue: toxicity. Proc Am Soc Clin Oncol 1991, 10:121.
83. Gisselbrecht C, Lepage E, Espie M, et al.: Cyclophosphamide, total body irradiation with autologous bone marrow support for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1987, 6:65.
84. Gisselbrecht C, LePage E, Extra J, et al.: Inflammatory and metastatic breast cancer: cyclophosphamide and total body irradiation with autologous bone marrow transplantation. In Autologous Bone Marrow Transplantation: Proceedings of the Fourth International Symposium. Edited by Dicke K, Spitzer G, Jagannath S, Evinger-Hodges M. Houston: University of Texas, MD Anderson Cancer Center Press; 1989:363-367.
85. Mulder N, Mulder P, Sleijfer D, et al.: Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer 1993, 29A:668-671.
86. Somlo G, Doroshow J, Forman S, et al.: High dose chemotherapy and stem cell rescue in the treatment of high risk breast cancer: prognostic indicators of progression free and overall survival. J Clin Oncol 1997, 15:2882-2893.
87. Roche H, Chevreau C, Hihura J, et al.: Intensive chemotherapy program with autologous bone marrow transplantation in non-metastatic inflammatory breast cancer: mature results [abstract]. 7th EORTC Breast Cancer Working Conference. Eur J Cancer 1996, 32A(suppl 2):36.
88. Maraninchi D, Piana L, Biaise D, et al.: Phase I and II studies of high dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplantation. In Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium. Edited by Dicke K, Spitzer TR, Jagannath S. Houston, TX: University of Texas Press; 1987:475-480
89. Perry J, Cruz J, Hopkins J, Neijstrom E, Muss H, Hurd D: High dose cyclophosphamide, thiotepa, and carboplatin (CTCb) with autologous stem cell transplantation (ASCT) for poor prognosis breast cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:93.
90. Ayash L, Elias A, Ibrahim J, et al.: High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:90a.
91. Adkins D, Brown R, beck E, et al.: Outcomes of high dose chemotherapy and autologous stem cell transplant in stage IIIB inflammatory breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:104a.
92. Nieto Y, Cagnoni P, Bearman D, Shpall E, Ross M, Jones R: High dose chemotherapy with cisplatin, cyclophosphamide and BCNU followed by autologous hematopoietic progenitor cell support for Inflammatory breast cancer [abstract]. Proc Am Soc Clin Oncol 1997, 16:124a.
93. Rosti G, Vertogen B, Ferrante P, et al.: High-dose mitoxantrone, thiotepa and cyclophosphamide with peripheral blood progenitor cells support for inflammatory breast carcinoma: an Italian study [abstract]. Proc Am Soc Clin Oncol 1997, 16:125a.
94. Bezwoda W, Seymour L, Dansey R: High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995, 13:2483-2489.
95. Rodenhuis S, Richel D, Baars J, et al.: A randomized single-institution study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in high-risk breast cancer [abstract]. Proc Am Assoc Cancer Res 1997, 38:438.
96. Hillner BE, Smith TJ, Desch CE: Estimating the cost-effectiveness of autologous bone marrow transplantation for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1991, 10:46.
97. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992, 267:2055-2061.